MicuRx is a privately-held biopharmaceutical company whose mission is to discover and develop antibiotics with improved safety profiles to improve the treatment of resistant bacterial infections. The lead compounds, contezolid (MRX-1) and contezolid acefosamil (MRX-4), next-generation oxazolidinones targeting methicillin resistant S. aureus (MRSA), were structure-designed to reduce hematological adverse events of this antibiotic class.